Home | About CDC | Press Room | Funding | A-Z Index | Centers, Institutes & Offices | Training & Employment | Contact Us
CDC Centers for Disease Control and Prevention Home Page
CDC en Español
Search:  
  Flu Home
  About the Flu
  Arrow Key Facts About Flu
  Arrow Preventing the Flu
  Arrow Flu Activity
  Arrow Q & A
  Arrow Info for Specific Groups
  For Health Professionals
  Arrow Vaccination
  Arrow Clinical Description & Diagnosis
  Arrow Background
  Arrow Training
  Arrow Flu Bulletins
  Arrow Infection Control
  Arrow Antivirals
  Arrow Patient Education
  Arrow References & Resources
  Arrow Surveillance
  See Also…
  Arrow Avian Flu
""    
 What's New | Contact Us
Influenza (Flu) - Protect Yourself and Your Loved Ones
Flu Home > Information for Health Care Professionals >
Background on Influenza
 
On this page:
Introduction
Biology of Influenza
More Information
 

Introduction(See note about the information provided here.)

Epidemics of influenza typically occur during the winter months and have been responsible for an average of approximately 36,000 deaths/year in the United States during 1990–1999. Influenza viruses also can cause pandemics, during which rates of illness and death from influenza-related complications can increase dramatically worldwide. Influenza viruses cause disease among all age groups. Rates of infection are highest among children, but rates of serious illness and death are highest among persons aged > 65 years and persons of any age who have medical conditions that place them at increased risk for complications from influenza.

Influenza vaccination is the primary method for preventing influenza and its severe complications. In this report from the Advisory Committee on Immunization Practices (ACIP), the primary target groups recommended for annual vaccination are 1) groups that are at increased risk for influenza-related complications (e.g., persons aged > 65 years and persons of any age with certain chronic medical conditions); 2) the group aged 50–64 years because this group has an elevated prevalence of certain chronic medical conditions; and 3) persons who live with or care for persons at high risk (e.g., health-care workers and household contacts who have frequent contact with persons at high risk and who can transmit influenza to persons at high risk). Vaccination is associated with reductions in influenza-related respiratory illness and physician visits among all age groups, hospitalization and death among persons at high risk, otitis media among children, and work absenteeism among adults. Although influenza vaccination levels increased substantially during the 1990s, further improvements in vaccine coverage levels are needed, chiefly among persons aged <65 years who are at increased risk for influenza-related complications among all racial and ethnic groups and among blacks and Hispanics aged > 65 years. ACIP recommends using strategies to improve vaccination levels, including using reminder/recall systems and standing orders programs. Although influenza vaccination remains the cornerstone for the control and treatment of influenza, information is also presented regarding antiviral medications, because these agents are an adjunct to vaccine.

Biology of Influenza(See note about the information provided here.)

Influenza A and B are the two types of influenza viruses that cause epidemic human disease. Influenza A viruses are further categorized into subtypes on the basis of two surface antigens: hemagglutinin (H) and neuraminidase (N). Influenza B viruses are not categorized into subtypes. Since 1977, influenza A (H1N1) viruses, influenza A (H3N2) viruses, and influenza B viruses have been in global circulation. In 2001, influenza A (H1N2) viruses that probably emerged after genetic reassortment between human A (H3N2) and A (H1N1) viruses began circulating widely. Both influenza A and B viruses are further separated into groups on the basis of antigenic characteristics. New influenza virus variants result from frequent antigenic change (i.e., antigenic drift) resulting from point mutations that occur during viral replication. Influenza B viruses undergo antigenic drift less rapidly than influenza A viruses.

A person's immunity to the surface antigens, including hemagglutinin, reduces the likelihood of infection and severity of disease if infection occurs. Antibody against one influenza virus type or subtype confers limited or no protection against another. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual incorporation of > 1 new strains in each year's influenza vaccine.

More Information

 

*  The text provided here is taken directly from Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (MMWR 28 May 2004;53[RR06]:1-40).

 

    Home   |   Policies and Regulations   |  Disclaimer   |  e-Government   |  FOIA   |   Contact Us  
Safer, Healthier People

Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: 404-639-3311 / Flu Public Inquiries: 800-232-2522 • español 800-232-0233 • TTY 800-243-7889
Clinician Information Line: 877-554-4625
FirstGovDHHS Department of Health
and Human Services